Brimarafenib

DB21706InvestigationalSmall molecule

Brimarafenib is a small molecule drug. The usage of the INN stem '-rafenib' in the name indicates that Brimarafenib is a Raf (rapidly accelerated fibrosarcoma) kinase inhibitor. Brimarafenib is under... Brimarafenib is under investigation in clinical trial NCT04249843 (Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors).

Mechanism: Pharmacologically active on RAF proto-oncogene serine/threonine-protein kinase, Serine/threonine-protein kinase A-Raf, and Serine/threonine-protein kinase B-raf
Curator reviewed
Formula / weight: C₂₄H₁₇F₃N₄O₄ · 482.419 g/mol (avg)
Code names: BGB-3245

Resolves to

Compound

UNIIGXS33OY2CBCAS1643326-82-2ChEMBLCHEMBL5800160

Structure

InChIKeyUSMWOBMHNWNPAP-FKBYEOEOSA-NSMILES[H][C@]12OC3=C(C=C(OC4=C5CCC(=O)N=C5NC=C4)C=C3)[C@@]1([H])[C@@H]2NC(=O)NC1=C(F)C=C(F)C(F)=C1

Targets

P04049RAF1P10398ARAFP15056BRAF

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Brimarafenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account